Objective
MD Anderson Cancer Center is a university hospital and global leader in cancer care, located in Houston, Texas. MD Anderson’s electronic health record (EHR), Epic, currently utilizes DDI warnings provided by First Databank (FDB), one of the major providers of drug databases in the nation. Based on internal assessments, DDI warnings accounted for 47% of all FDB medication warnings from January 2019 through June 2019. Due to limitations in functionality, these DDI warnings do not take patient-specific factors, such as age, cardiovascular history, or electrolytes, into consideration, and alerts generated for QTc-prolonging medications are overridden more than 90% of the time. FDB provides all possible DDI warnings, leaving each institution to determine which warnings to make visible and which ones to filter or keep silent. Filtered warnings determined to be of low priority are turned off by the institution to avoid unnecessary alerts. Replacing the DDI warnings with a custom alert triggered by an accurate QTc-prolongation risk score would be beneficial in reducing overall alert burden and fatigue. The aim of our study is to decrease false positive DDI warnings for QTc-prolonging medications by 20% through triggering a custom alert based on a patient-specific QTc-prolongation risk score at MD Anderson Cancer Center. The accuracy of the QTc-prolongation risk score and its ability to predict the risk for QTc prolongation will be determined based on sensitivity and specificity calculations.